Company: STAA
Filing Date: 2025-10-27
Form Type: DEFA14A
Source: 0001193125-25-250966
Chunk: 5

Company: STAAR SURGICAL CO
Filing Date: 2025-10-27
Form: DEFA14A
Chunk 5
---
 Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon

STAAR Special Meeting of Stockholders Postponed to December 3, 2025

LAKE FOREST, Calif., October27, 2025 –STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer Lens (ICL) announced that, in light of ongoing discussions with Alcon (SIX/NYSE: ALC), STAAR’s Special Meeting of Stockholders in connection with STAAR’s merger agreement with Alcon
(the “Special Meeting”), which was previously adjourned until November 6, 2025 at 8:30 a.m. Pacific Time, has been postponed until December 3, 2025 at 8:30 a.m. Pacific Time. The new record date for the Special Meeting is the
close of business on October 24, 2025. Stockholders who hold shares as of the record date will be eligible to vote at the postponed Special Meeting on December 3, 2025, and STAAR will be providing a notice of the meeting and other
materials to such stockholders in advance of the meeting date.

Stockholders with questions about voting their shares should contact STAAR’s proxy
solicitor, Innisfree M&A Incorporated, toll-free at +1 877-750-8233. Banks and brokerage firms, please call +1 212-750-5833.

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need
for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the
eye’s natural crystalline lens. Its EVO ICL product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75
countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about